Recent

% | $
Quotes you view appear here for quick access.

SAVİENT PHARM AŞ Message Board

  • lempe39398 lempe39398 Aug 27, 2013 2:06 PM Flag

    LOL Ferrari updated his profile, look at what he says. I hope this is the case of broken clock being right twice a day

    "Operational Excellence: Implemented the first cost containment measures, clinical programs and an aggressive pricing program, setting Savient to being a profitable company by the end of 2014"

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Lempe: As soon as SVNT correctly reprices K to around $10,000/dose or higher 3Q13 SVNT will be immediately profitable by YE 2014......They guided sufficient cash for approx another 12 months 2Q13.......In just a few months analysts will have rev estimates of around $125 mil for 2014.....

      Sentiment: Strong Buy

    • He also excelled in "full P&L leadership"..... By the end of 2014, SVNT might be profitable but in the hands of its creditors.
      ------------------------------------------------------------------------------------------------------------------------------------
      Louis Ferrari's Summary

      PRESIDENT/CEO/GENERAL MANAGER – PHARMA/BIOTECH INDUSTRY
      Diverse commercial and clinical leadership experience in functional disciplines from sales and marketing to clinical and finance, most recently attaining level of President/CEO for publicly traded biopharm company.
       Growth Strategy: Developed alternative use drug indications to expand patient population...more needed
       Operational Excellence: Implemented the first cost containment measures, clinical programs and an aggressive pricing program, setting Savient to being a profitable company by the end of 2014. Member of J&J owned Ortho-BioTech company's Leadership Operations Committee. Thorough understanding of the clinical and commercial regulatory environment and its impact on internal operations.
       Financial Management: Full P&L leadership. Restructured convertible notes to senior secured notes to generate $44 million.
       Personal Philosophy: Dedication to help improve the quality of life of patients, and make a positive difference in the lives of their families and care givers.
       Board Experience: Member of J&J's Ortho-Biotech and post-merger Centocor Ortho-Biotech Boards developing corporate and brand strategies
      Sales&Marketing,Clinical affairs both US and Ex-US

      Specialties: Pharmaceutical Sales and Marketing.
      ------------------------------------------------------------------------------------------------------------------------------------

    • "profitable company by the end of 2014"

      Do we need to know more from the former CEO?
      And he has not sold his shares.

      Sentiment: Strong Buy